Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation reports news about its global life sciences business, which supplies reagents, analytical instruments and precision diagnostics for research, biopharmaceutical, biotechnology and clinical diagnostic customers. Company updates commonly cover financial results, cash dividends, investor conference presentations and demand trends across large pharma, emerging biotech and academic markets.
Product news centers on Bio-Techne's R&D Systems™, Bio-Techne Spatial™ and Bio-Techne Diagnostics™ portfolios. Recent recurring themes include spatial biology workflow additions for the COMET™ suite, SPYRE™ antibody panels and amplification kits, GMP-grade reagents for cell and gene therapy workflows, and the Ella cartridge-based immunoassay platform for translational research and clinical applications.
Bio-Techne Corporation (NASDAQ: TECH) announced that CEO Chuck Kummeth will present at the Credit Suisse 31st Annual Healthcare Conference on November 9, 2022, at 8:35 a.m. PST. A live webcast will be available on the company's Investor Relations website.
Bio-Techne specializes in manufacturing purified proteins and reagent solutions, generating approximately $1.1 billion in net sales in fiscal 2022, with around 3,000 employees globally. Its diverse portfolio supports biomedical researchers and clinical laboratories.
Bio-Techne Corporation (NASDAQ: TECH) announced a quarterly dividend of $0.32 per share for the quarter ending September 30, 2022, payable on November 28, 2022. Shareholders of record by November 14, 2022, will receive this dividend. Additionally, a four-for-one stock split was approved, providing three extra shares for each held share to those on record by the same date. The split will take effect post-trading on November 29, 2022. Bio-Techne reported approximately $1.1 billion in net sales in fiscal 2022.
Bio-Techne Corporation (NASDAQ: TECH) reported a strong performance for Q1 FY2023, with organic revenue growth of 7% to $269.7 million. GAAP EPS rose to $2.21, up from $1.69 last year, supported by gains on investments. The Diagnostics and Genomics segment led the growth with 17% organic growth, particularly from the ExoDx Prostate test, which saw a 70% increase in tests performed and over 100% revenue growth year-over-year. Operating cash flow also improved by 16% to $56.1 million.
Bio-Techne Corporation (NASDAQ: TECH) announced the presentation of its diagnostic lab solutions by Asuragen at the Association for Molecular Pathology (AMP) annual meeting from November 1-5, 2022, in Phoenix, AZ. The company introduced new Armored DNA™ molecular controls for monkeypox and related viruses to enhance clinical testing capabilities. Workshops and posters will focus on genetic testing workflows and molecular controls for emerging diseases, including SARS-CoV-2. These developments aim to improve lab testing accessibility and response efficiency to public health threats.
Bio-Techne Corporation (NASDAQ: TECH) announced a proof-of-concept study from Exosome Diagnostics, revealing the feasibility of using an exosome-based platform for monitoring astronauts' health in space. The peer-reviewed study, published in npj Microgravity, identifies a potential method to diagnose spaceflight-associated neuro-ocular syndrome (SANS), which affects returning astronauts. Exosomes can be extracted noninvasively from biofluids, offering insights into health changes due to microgravity. This innovative approach aims to enhance astronaut health and has broader applications in precision medicine on Earth.
Bio-Techne Corporation (NASDAQ: TECH) has launched three new TSA Vivid Fluorophores designed for highly sensitive RNA detection in various biological samples. Optimized for use with the existing RNAscope ISH technology, these fluorophores aim to enhance RNA biomarker detection with unmatched clarity. The launch is supported by over 6,600 peer-reviewed publications, ensuring reliability. This move aligns with the company's growth strategy to leverage its unique capabilities in fluorescent imaging, contributing to advancements in cellular research and therapeutic development.
Bio-Techne Corporation (NASDAQ: TECH) launched three new Simple Plex™ Adeno-Associated Virus (AAV) viral titer assays for quantifying intact AAV capsids. Developed in collaboration with PROGEN, these assays—AAV1, AAV6, and AAV8—offer automated, reproducible methods for viral particle analysis. The assays are designed to meet the growing need for efficient titration, enhancing detection range with fewer sample dilutions. Bio-Techne's sales reached approximately $1.1 billion in fiscal 2022, and the new products expand their protein analysis portfolio.
Bio-Techne Corporation (NASDAQ: TECH) will host a conference call on November 1, 2022, at 8:00 a.m. CDT to review its first quarter 2023 financial results. Investors can access the call via dial-in or webcast. A recorded rebroadcast will be available from 11:00 a.m. CDT on the same day until 11:00 p.m. CST on December 1, 2022. In fiscal 2022, Bio-Techne generated approximately $1.1 billion in net sales and has a diverse portfolio, including reagents, diagnostic products, and genomic tools vital for biomedical research.
Bio-Techne Corporation (NASDAQ: TECH) has introduced new automated co-detection assays for the Roche DISCOVER ULTRA Platform, expanding its RNAscope ISH technology. These assays will allow simultaneous RNA and protein detection in tissue samples, potentially enhancing research in various diseases. The RNAscope platform is noted for its specificity and sensitivity, supported by over 6,600 peer-reviewed publications. With an expansive catalog of probes, Bio-Techne aims to accelerate research and therapeutic development in tissue diagnostics.
ScaleReady, a joint venture involving Bio-Techne (NASDAQ: TECH), announces the launch of the Cue Cell Processing System, designed exclusively for cell and gene therapy organizations. This innovative system automates complex, labor-intensive tasks, enhancing precision in cell processing workflows. Cue is customizable, ensuring that final formulations meet specifications consistently. Available in the U.S., Canada, and Europe, it also supports requests for regulatory documentation for advanced applications. This launch positions ScaleReady as a leader in the evolving market of cell and gene therapies.